Business Case

Developed a lifecycle-revenue-maximizing pricing strategy for a large pharma CNS treatment

Our client, a large pharmaceutical company specializing in CNS disorders, intended to introduce a groundbreaking CNS treatment and sought to understand a U.S. life-cycle pricing strategy to optimize gross-to-net revenues. LSC combined analysis of the channel mix, analogue price benchmarking, target patient demographic analysis and focused primary research to validate preliminary hypotheses on best practices. The holistic assessment culminated in a tailored pricing and contracting strategy that centered around the Medicaid patient demographic that was expected to represent most of the drug volume. When modeled, the strategy maximized gross-to-net pricing for our client.